ADVFN Logo
Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

GNVC Genvec, Inc.

7.193
0.00 (0.00%)
Mar 27 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 0
Bid Price 0.35
Ask Price 7.19
News -
Company Name Stock Ticker Symbol Market Type
Genvec, Inc. GNVC NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.00 0.00% 7.193 20:00:00
Open Price Low Price High Price Close Price Prev Close
7.193 7.193
Trades Volume Avg Volume
0 0 -
Last Trade Time Type Quantity Stock Price Currency
- 0 $ 7.193 USD

Genvec, Inc. Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 7.60M - - - -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Genvec, Inc. News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No GNVC Message Board. Create One! See More Posts on GNVC Message Board See More Message Board Posts

Historical GNVC Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.000.000.000.0000.000.00%
1 Month0.000.000.000.0000.000.00%
3 Months0.000.000.000.0000.000.00%
6 Months0.000.000.000.0000.000.00%
1 Year0.000.000.000.0000.000.00%
3 Years0.000.000.000.0000.000.00%
5 Years0.000.000.000.0000.000.00%

Genvec, Inc. Description

Genvec Inc was incorporated under the laws of the state of Delaware on December 7, 1992.The Company is a biopharmaceutical company using differentiated, proprietary technologies to create superior therapeutics and vaccines. Its development programs address therapeutic areas such as hearing loss and balance disorders; as well as vaccines against infectious diseases including respiratory syncytial virus or RSV, herpes simplex virus or HSV, and malaria. In the area of animal health the Company is developing vaccines against foot-and-mouth disease or FMD. In collaboration with Novartis, the Companys hearing and balance disorders program is focused on the restoration of hearing and balance function through the regeneration of critical cells of the inner ear.

Your Recent History

Delayed Upgrade Clock